ARTICLE | Product Development
Cullinan adds T cell engagers to modality migration from cancer to autoimmunity
Cullinan raises a $280 million PIPE to develop CLN-978 for lupus
April 17, 2024 12:36 AM UTC
The pivot of Cullinan Oncology — now Cullinan Therapeutics — to autoimmune diseases is the latest example of a company seeing opportunity in repositioning cancer modalities for autoimmune diseases.
Cullinan Therapeutics Inc. (NASDAQ:CGEM) announced plans to start a Phase I trial next quarter of CLN-978 to treat systemic lupus erythematosus (SLE). The bispecific T cell engager, which targets CD3 and CD19, had been in development for B cell non-Hodgkin’s lymphoma. The company said it will now exclusively focus the program on autoimmune diseases...